

Performance in Delivering Clinical Trial Research Q3 2017 - 2018
Time to Target (Commercial Contracts)
Studies that have Closed to Recruitment in the Previous 12 months

Research Ethics Number	IRAS number	Name of Trial	Agreed Target of patients	Target Range Agreed? (min/max)	Target Date Agreed?	Total Recruited by Agreed Target Date	Total Number of Study Participant	Recruitment end date	Trial Status	Target met	Comments
15/SS/0032	165287	An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease	1	No	Yes (09/12/2015)	4	4	09/02/2017	Recruitment Finished	Yes	Study closed. Recruitment target met
15/SC/0432	181387	A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects with Treatment-resistant Depression TRANSFORM (ESKETINTRD3005)	2	No	Yes (24/05/2017)	0	0	15/05/2017	Withdrawn By Sponsor	No	Sponsor terminated recruitment early due to global target being met
15/SC/0434	181955	An open-label, long-term, safety and efficacy study of intranasal Esketamine in Treatment-resistant Depression in Adults SUSTAIN-2 (ESKETINTRD3004)	4	No	Yes (31/07/2017)	4	4	27/03/2017	Recruitment Finished	Yes	Study closed. Recruitment target met
16/SC/0363	205067	RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER REGISTRATION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TTP488 IN PATIENTS WITH MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINE (STEADFAST)	3	No	Yes (24/10/2016)	5	5	10/04/2017	Recruitment Finished	Yes	Study closed. Recruitment target met
16/LO/1820	212826	Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa (OPIANT)	10	yes	Yes (31/01/2018)	10	0	09/08/2017	Withdrawn By Sponsor	No	Study closed due to lack resource delivery
16/LO/1086	203002	A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a MonoAminergic antidepressant in Adults with Major Depressive Disorder (CNT0136 Sirukumab)	3	Yes	Yes (31/10/2017)	3	1	31/12/2017	Recruitment Finished	no	Difficult study to recruit to nationally and only 1 site managed to recruit target
16/SC/0435	212314	54135419TRD3008 An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression Safety and Sustainment of Esketamine Treatment Response With Repeated Doses at Intervals Determined by Symptom Severity (SUSTAIN-	2	yes	31/03/2018	2	2	31/08/2017	Recruitment Finished	Yes	